Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 4:51 PM ET

Pharmaceuticals

Company Overview of Lantheus Medical Imaging, Inc.

Company Overview

Lantheus Medical Imaging, Inc. develops, manufactures, and distributes diagnostic medical imaging products worldwide. The company offers imaging agents that assist in the diagnosis of heart, vascular, and other diseases using nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies. It offers DEFINITY, an injectable agent used during cardiac ultrasound or echocardiography for patients with suboptimal echocardiograms; TechneLite, a technetium generator used in nuclear medicine procedures; and Xenon Xe 133 Gas, a radiopharmaceutical gas that is used to assess pulmonary function. The company also provides Cardiolite, an injectable and technetium-labeled imaging agent...

331 Treble Cove Road

North Billerica, MA 01862

United States

Founded in 1956

524 Employees

Phone:

978-671-8001

Fax:

978-671-8860

Key Executives for Lantheus Medical Imaging, Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer
Age: 52
Chief Operating Officer
Age: 54
Vice President, General Counsel and Secretary
Age: 53
Chief Medical Officer
Age: 64
Compensation as of Fiscal Year 2014.

Lantheus Medical Imaging, Inc. Key Developments

Lantheus Medical Imaging, Inc. Promotes Mary Anne Heino to the Position of Chief Operating Officer

On March 16, 2015, Lantheus Medical Imaging, Inc. announced its promotion of Mary Anne Heino to the position of Chief Operating Officer. Ms. Heino, age 55, had previously served as the company's Chief Commercial Officer, a position she held since joining the company in April 2013. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012.

Lantheus Medical Imaging, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Asset Write-Off Charges for the Fourth Quarter Ended December 31, 2014

Lantheus Medical Imaging, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenues were $76,969,000 against $71,668,000 last year. Operating income was $11,800,000 against operating loss of $1,334,000 last year. Income before income taxes was $1,869,000 against loss before income taxes of $11,555,000 last year. Net income was $300,000 against net loss of $12,302,000 last year. Net income, as adjusted was $1,510,000 against net loss, as adjusted of $6,120,000 last year. EBITDA was $17,496,000 against $4,710,000 last year. Adjusted EBITDA was $19,363,000 against $15,157,000 last year. Net cash used in operating activities was $3,875,000 against $3,856,000 last year. Capital expenditures were $2,834,000 against $1,299,000 last year. For the year, revenues were $301,600,000 against $283,672,000 last year. Operating income was $41,809,000 against operating loss of $19,014,000 last year. Income before income taxes was $26,000 against loss before income taxes of $60,664,000 last year. Net loss was $1,169,000 against $61,678,000 last year. Net income, as adjusted was $41,000 against net loss, as adjusted of $48,708,000 last year. EBITDA was $60,557,000 against $6,789,000 last year. Adjusted EBITDA was $70,775,000 against $38,360,000 last year. Net cash provided by operating activities was $11,573,000 against net cash used in operating activities of $15,678,000 last year. Capital expenditures were $8,137,000 against $5,010,000 last year. For the quarter, asset write-off was $107,000 against $18,091,000 last year.

Lantheus Medical Imaging, Inc., Q4 2014 Earnings Call, Mar 04, 2015

Lantheus Medical Imaging, Inc., Q4 2014 Earnings Call, Mar 04, 2015

Similar Private Companies By Industry

Company Name Region
VerCo Inc. United States
Salvona Technologies LLC United States
Larasan Pharmaceutical Corporation United States
Kalidex Pharmaceuticals, Inc. United States
Health & Nutrition Systems International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lantheus Medical Imaging, Inc., please visit www.lantheus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.